385 related articles for article (PubMed ID: 28521846)
1. Measures of suicidality in phase 3 clinical trials of levomilnacipran ER in adults with major depressive disorder.
Thase ME; Gommoll C; Chen C; Kramer K; Khan A; Durgam S
CNS Spectr; 2017 Dec; 22(6):475-483. PubMed ID: 28521846
[TBL] [Abstract][Full Text] [Related]
2. Suicidal ideation and behavior in adults with major depressive disorder treated with vortioxetine: post hoc pooled analyses of randomized, placebo-controlled, short-term and open-label, long-term extension trials.
Mahableshwarkar AR; Affinito J; Reines EH; Xu J; Nomikos G; Jacobsen PL
CNS Spectr; 2020 Jun; 25(3):352-362. PubMed ID: 31199210
[TBL] [Abstract][Full Text] [Related]
3. Effects of vilazodone on suicidal ideation and behavior in adults with major depressive disorder or generalized anxiety disorder: post-hoc analysis of randomized, double-blind, placebo-controlled trials.
Thase ME; Edwards J; Durgam S; Chen C; Chang CT; Mathews M; Gommoll CP
Int Clin Psychopharmacol; 2017 Sep; 32(5):281-288. PubMed ID: 28538024
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of levomilnacipran ER across symptoms of major depressive disorder: a post hoc analysis of 5 randomized, double-blind, placebo-controlled trials.
McIntyre RS; Gommoll C; Chen C; Ruth A
CNS Spectr; 2016 Oct; 21(5):385-392. PubMed ID: 27292817
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of functional health and well-being in patients receiving levomilnacipran ER for the treatment of major depressive disorder.
Blum SI; Tourkodimitris S; Ruth A
J Affect Disord; 2015 Jan; 170():230-6. PubMed ID: 25259674
[TBL] [Abstract][Full Text] [Related]
6. Duloxetine: meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorder.
Acharya N; Rosen AS; Polzer JP; D'Souza DN; Perahia DG; Cavazzoni PA; Baldessarini RJ
J Clin Psychopharmacol; 2006 Dec; 26(6):587-94. PubMed ID: 17110815
[TBL] [Abstract][Full Text] [Related]
7. Relapse prevention with levomilnacipran ER in adults with major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled study.
Durgam S; Chen C; Migliore R; Prakash C; Thase ME
Depress Anxiety; 2019 Mar; 36(3):225-234. PubMed ID: 30675739
[TBL] [Abstract][Full Text] [Related]
8. Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study.
Bakish D; Bose A; Gommoll C; Chen C; Nunez R; Greenberg WM; Liebowitz M; Khan A
J Psychiatry Neurosci; 2014 Jan; 39(1):40-9. PubMed ID: 24144196
[TBL] [Abstract][Full Text] [Related]
9. Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant--what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2013 Nov; 67(11):1089-104. PubMed ID: 24016209
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis of efficacy and treatment-emergent suicidality in adults by psychiatric indication and age subgroup following initiation of paroxetine therapy: a complete set of randomized placebo-controlled trials.
Carpenter DJ; Fong R; Kraus JE; Davies JT; Moore C; Thase ME
J Clin Psychiatry; 2011 Nov; 72(11):1503-14. PubMed ID: 21367354
[TBL] [Abstract][Full Text] [Related]
11. A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder.
Sambunaris A; Bose A; Gommoll CP; Chen C; Greenberg WM; Sheehan DV
J Clin Psychopharmacol; 2014 Feb; 34(1):47-56. PubMed ID: 24172209
[TBL] [Abstract][Full Text] [Related]
12. The effects of levomilnacipran ER in adult patients with first-episode, highly recurrent, or chronic MDD.
Kornstein SG; Gommoll C; Chen C; Kramer K
J Affect Disord; 2016 Mar; 193():137-43. PubMed ID: 26773906
[TBL] [Abstract][Full Text] [Related]
13. Acute and longer-term safety results from a pooled analysis of duloxetine studies for the treatment of children and adolescents with major depressive disorder.
Emslie GJ; Wells TG; Prakash A; Zhang Q; Pangallo BA; Bangs ME; March JS
J Child Adolesc Psychopharmacol; 2015 May; 25(4):293-305. PubMed ID: 25978741
[TBL] [Abstract][Full Text] [Related]
14. Effect of adjunctive pimavanserin on suicidal ideation in patients with major depression: Analysis of the CLARITY study.
Shelton RC; Fava M; Freeman MP; Thase ME; Papakostas GI; Jha MK; Trivedi MH; Dirks B; Liu K; Stankovic S
J Affect Disord; 2020 Dec; 277():478-485. PubMed ID: 32871535
[TBL] [Abstract][Full Text] [Related]
15. The controversial link between antidepressants and suicidality risks in adults: data from a naturalistic study on a large sample of in-patients with a major depressive episode.
Seemüller F; Riedel M; Obermeier M; Bauer M; Adli M; Mundt C; Holsboer F; Brieger P; Laux G; Bender W; Heuser I; Zeiler J; Gaebel W; Jäger M; Henkel V; Möller HJ
Int J Neuropsychopharmacol; 2009 Mar; 12(2):181-9. PubMed ID: 18662490
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study.
Montgomery SA; Mansuy L; Ruth A; Bose A; Li H; Li D
J Clin Psychiatry; 2013 Apr; 74(4):363-9. PubMed ID: 23656841
[TBL] [Abstract][Full Text] [Related]
17. A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder.
Emslie GJ; Prakash A; Zhang Q; Pangallo BA; Bangs ME; March JS
J Child Adolesc Psychopharmacol; 2014 May; 24(4):170-9. PubMed ID: 24815533
[TBL] [Abstract][Full Text] [Related]
18. A double-blind efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder.
Atkinson SD; Prakash A; Zhang Q; Pangallo BA; Bangs ME; Emslie GJ; March JS
J Child Adolesc Psychopharmacol; 2014 May; 24(4):180-9. PubMed ID: 24813026
[TBL] [Abstract][Full Text] [Related]
19. Analysis of suicidality in pooled data from 2 double-blind, placebo-controlled aripiprazole adjunctive therapy trials in major depressive disorder.
Weisler RH; Khan A; Trivedi MH; Yang H; Eudicone JM; Pikalov A; Tran QV; Berman RM; Carlson BX
J Clin Psychiatry; 2011 Apr; 72(4):548-55. PubMed ID: 20816039
[TBL] [Abstract][Full Text] [Related]
20. Effects of levomilnacipran ER on fatigue symptoms associated with major depressive disorder.
Freeman MP; Fava M; Gommoll C; Chen C; Greenberg WM; Ruth A
Int Clin Psychopharmacol; 2016 Mar; 31(2):100-9. PubMed ID: 26584326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]